Home › CIRM

CIRM

News Story
12/7/2012
Posted by Mark Reback
The California Institute for Regenerative Medicine board should be restructured to shore up the integrity of its grant process, an Institute of Medicine report says. The board of California's stem cell funding agency is rife with conflicts of interest and should be restructured to improve the integrity of its grant-making process, according to...
News Release
12/6/2012
Posted by John M. Simpson
SANTA MONICA, CA – Consumer Watchdog Thursday welcomed a report from the prestigious Institute of Medicine (IOM) calling for sweeping reforms in governance at California’s stem cell agency and an end to the board’s built-in conflicts of interest.   The report said that “far too many board members represent...
News Story
12/6/2012
Posted by Mark Reback
Agency should split operations from policy, add more oversight committee members without conflicts California's $3 billion stem cell agency should reduce its built-in conflicts of interests or risk losing effectiveness, according to a report released today from the prestigious National Academy of Sciences. The academy's report said the...
News Story
12/6/2012
Posted by Mark Reback
The California Institute of Regenerative Medicine received a mixture of praise and hard-to-enact recommendations from an august scientific body today. Last summer, CIRM asked the Institute of Medicine to gather a group of experts to assess the stem-cell institute’s performance, which has distributed more than $1.3 billion to California...
News Story
12/6/2012
Posted by Mark Reback
A review of California's stem cell research funding agency proposed changes to the agency's governing structure and commercial goals while praising its results so far. The 124-page report from the Institute of Medicine recycles many conflict of interest and intellectual property concerns that have dogged the San Francisco-based California...
News Story
3/18/2012
Posted by Mark Reback
LOS ANGELES (AP) -- The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions. The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds...
News Story
12/9/2011
Posted by Mark Reback
Touted seven years ago as a way to develop "breakthrough cures" for an array of life-threatening ailments, California's $3 billion taxpayer-financed stem cell agency still has no treatments on the market and is at a critical juncture that could determine how much longer it stays in operation. The agency will dole out the last of...